17 results on '"Stephen Morris-Jones"'
Search Results
2. Management and Clinical Outcomes of 37 Patients with Necrotizing Otitis Externa: Retrospective Review of a Standardized 6-Week Treatment Pathway
- Author
-
Ankush Dhariwal, Joseph G Manjaly, Bhavesh Patel, Stephen Morris-Jones, Kate David, Priya Khetarpal, Tim Beale, Nishchay Mehta, and Sarah Logan
- Subjects
Otorhinolaryngology ,RF1-547 - Published
- 2023
- Full Text
- View/download PDF
3. Clinical, microbiological characteristics and predictors of mortality in patients with carbapenemase-producing Enterobacterales bloodstream infections: a multicentre study
- Author
-
Vanesa Anton-Vazquez, Terry John Evans, Samitha Fernando, Donald Somasunderam, Kate David, Mark Melzer, Lois Hawkins, Stephen Morris-Jones, Mauricio Arias, Borana Drazho, Martino Dall’Antonia, and Timothy Planche
- Subjects
Carbapenemase-producing enterobacterales (CPE) ,OXA-48 ,KPC ,MBL ,NDM ,Bloodstream infection ,Infectious and parasitic diseases ,RC109-216 ,Public aspects of medicine ,RA1-1270 - Abstract
Summary: Objectives: To investigate the clinical, microbiological characteristics and outcomes of patients with bloodstream infections (BSI) due to carbapenemase-producing Enterobacterales (CPE). Methods: A multicentre retrospective observational study of patients with BSIs due to CPE admitted to six UK hospitals was conducted between 2011 and 2021. Multivariate analysis was used to identify factors predicting 30-day case fatality rate (CFR). Results: There were 84 episodes of CPE-BSIs, 37 (44%) due to OXA-48, 35 (42%) to metallo-betalactamases (MBL) and 12 (14%) to KPC. 63% of patients were male with a median age of 64 years. Common organisms included Klebsiella spp. (61%), Escherichia coli (20%) and Enterobacter spp. (13%). Urinary devices were more often involved in OXA-48 BSIs (12/37; 32%) compared to infections caused by MBL and KPC (4/35; 11% and 1/12; 8%; P = 0.046). In contrast, central venous catheters were more frequently present in KPC-BSIs (10/12; 92%) compared with OXA-48 and MBL (11/37; 30% and 20/35; 57%; P = 0.002). Effective definitive antimicrobials were received by 72/84 (86%) patients, comprising monotherapy (32/72; 44%) or combination therapy (40/72; 56%). 30-day case fatality rate (CFR) was 38%. Sepsis or septic shock was associated with death [OR 3.81 (CI 1.19–12.14), P = 0.024]. Conclusion: Strategies targeting high-risk patients and adherence to infection prevention bundles for urinary devices and central venous catheters can reduce OXA-48 and KPC-BSIs. Early recognition and management of severe sepsis, prompt initiation of appropriate antimicrobial therapy and development of novel antimicrobials are crucial to mitigate the high CFR associated with CPE-BSIs.
- Published
- 2023
- Full Text
- View/download PDF
4. Bedaquiline as Treatment for Disseminated Nontuberculous Mycobacteria Infection in 2 Patients Co-Infected with HIV
- Author
-
Eliza Gil, Nicola Sweeney, Veronica Barrett, Stephen Morris-Jones, Robert F. Miller, Victoria J. Johnston, and Michael Brown
- Subjects
bedaquiline ,antibacterial drugs ,antitubercular drugs ,antiinfective drugs ,Mycobacteriaceae ,Mycobacterium ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Abstract
Nontuberculous mycobacteria can cause disseminated infections in immunocompromised patients and are challenging to treat because of antimicrobial resistance and adverse effects of prolonged multidrug treatment. We report successful treatment with bedaquiline, a novel antimycobacterial drug, as part of combination therapy for 2 patients with disseminated nontuberculous mycobacteria co-infected with HIV.
- Published
- 2021
- Full Text
- View/download PDF
5. Acute otitis externa: Consensus definition, diagnostic criteria and core outcome set development.
- Author
-
Matthew E Smith, John C Hardman, Nishchay Mehta, Gareth H Jones, Rishi Mandavia, Caroline Anderson, Maha Khan, Aula Abdelaziz, Bakir Al-Dulaimy, Nikul Amin, Rajesh Anmolsingh, Bilal Anwar, Manohar Bance, Katherine Belfield, Mahmood Bhutta, Ruaridh Buchanan, Deepak Chandrasekharan, Michael Chu, Srikanth Chundu, Katherine Conroy, Gemma Crundwell, Mat Daniel, Jessica Daniels, Sujata De, Sian Dobbs, Jayesh Doshi, Matthew Farr, Tanjinah Ferdous, Eleni Fragkouli, Simon Freeman, Samit Ghosh, Emma Gosnell, S Alam Hannan, Elliot Heward, Faisal Javed, Deepa John, Helen Nicholls, Anand V Kasbekar, Haroon Khan, Hammad Khan, Sadie Khwaja, Bhik Kotecha, Madhankumar Krishnan, Nirmal Kumar, Tamara Lamb, Hannah Lancer, Joseph G Manjaly, Marcos Martinez Del Pero, Fiona McClenaghan, Kristijonas Milinis, Nina Mistry, Hassan Mohammed, Elizabeth Morris, Stephen Morris-Jones, Jessica Padee, Surojit Pal, Sanjay Patel, Agamemnon Pericleous, Asad Qayyum, Maral Rouhani, Haroon Saeed, Mirusanthan Santhiyapillai, Kay Seymour, Sunil Sharma, Richard Siau, Arvind Singh, Emma Stapleton, Kate Stephenson, Gill Stynes, Bharathi Subramanian, Neil Summerfield, Chloe Swords, Aaron Trinidade, Antonia Tse, Emmanuel Twumasi, Harmony Ubhi, Samit Unadkat, Ananth Vijendren, Joe Wasson, Glen Watson, Glennis Williams, Janet Wilson, Alexander Yao, Ahmed Youssef, Simon K W Lloyd, James R Tysome, and INTEGRATE (The UK ENT Trainee Research Network)
- Subjects
Medicine ,Science - Abstract
ObjectiveEvidence for the management of acute otitis externa (AOE) is limited, with unclear diagnostic criteria and variably reported outcome measures that may not reflect key stakeholder priorities. We aimed to develop 1) a definition, 2) diagnostic criteria and 3) a core outcome set (COS) for AOE.Study designCOS development according to Core Outcome Measures in Effectiveness Trials (COMET) methodology and parallel consensus selection of diagnostic criteria/definition.SettingStakeholders from the United Kingdom.Subjects and methodsComprehensive literature review identified candidate items for the COS, definition and diagnostic criteria. Nine individuals with past AOE generated further patient-centred candidate items. Candidate items were rated for importance by patient and professional (ENT doctors, general practitioners, microbiologists, nurses, audiologists) stakeholders in a three-round online Delphi exercise. Consensus items were grouped to form the COS, diagnostic criteria, and definition.ResultsCandidate COS items from patients (n = 28) and literature (n = 25) were deduplicated and amalgamated to a final candidate list (n = 46). Patients emphasised quality-of-life and the impact on daily activities/work. Via the Delphi process, stakeholders agreed on 31 candidate items. The final COS covered six outcomes: pain; disease severity; impact on quality-of-life and daily activities; patient satisfaction; treatment-related outcome; and microbiology. 14 candidate diagnostic criteria were identified, 8 reaching inclusion consensus. The final definition for AOE was 'diffuse inflammation of the ear canal skin of less than 6 weeks duration'.ConclusionThe development and adoption of a consensus definition, diagnostic criteria and a COS will help to standardise future research in AOE, facilitating meta-analysis. Consulting former patients throughout development highlighted deficiencies in the outcomes adopted previously, in particular concerning the impact of AOE on daily life.
- Published
- 2021
- Full Text
- View/download PDF
6. Comprehensive plasma proteomic profiling reveals biomarkers for active tuberculosis
- Author
-
Diana J. Garay-Baquero, Cory H. White, Naomi F. Walker, Marc Tebruegge, Hannah F. Schiff, Cesar Ugarte-Gil, Stephen Morris-Jones, Ben G. Marshall, Antigoni Manousopoulou, John Adamson, Andres F. Vallejo, Magdalena K. Bielecka, Robert J. Wilkinson, Liku B. Tezera, Christopher H. Woelk, Spiros D. Garbis, and Paul Elkington
- Subjects
Infectious disease ,Medicine - Abstract
BACKGROUND Tuberculosis (TB) kills more people than any other infection, and new diagnostic tests to identify active cases are required. We aimed to discover and verify novel markers for TB in nondepleted plasma.METHODS We applied an optimized quantitative proteomics discovery methodology based on multidimensional and orthogonal liquid chromatographic separation combined with high-resolution mass spectrometry to study nondepleted plasma of 11 patients with active TB compared with 10 healthy controls. Prioritized candidates were verified in independent UK (n = 118) and South African cohorts (n = 203).RESULTS We generated the most comprehensive TB plasma proteome to date, profiling 5022 proteins spanning 11 orders-of-magnitude concentration range with diverse biochemical and molecular properties. We analyzed the predominantly low–molecular weight subproteome, identifying 46 proteins with significantly increased and 90 with decreased abundance (peptide FDR ≤ 1%, q ≤ 0.05). Verification was performed for novel candidate biomarkers (CFHR5, ILF2) in 2 independent cohorts. Receiver operating characteristics analyses using a 5-protein panel (CFHR5, LRG1, CRP, LBP, and SAA1) exhibited discriminatory power in distinguishing TB from other respiratory diseases (AUC = 0.81).CONCLUSION We report the most comprehensive TB plasma proteome to date, identifying novel markers with verification in 2 independent cohorts, leading to a 5-protein biosignature with potential to improve TB diagnosis. With further development, these biomarkers have potential as a diagnostic triage test.FUNDING Colciencias, Medical Research Council, Innovate UK, NIHR, Academy of Medical Sciences, Program for Advanced Research Capacities for AIDS, Wellcome Centre for Infectious Diseases Research.
- Published
- 2020
- Full Text
- View/download PDF
7. Rapid identification of a Mycobacterium tuberculosis full genetic drug resistance profile through whole genome sequencing directly from sputum
- Author
-
Camus Nimmo, Ronan Doyle, Carrie Burgess, Rachel Williams, Rebecca Gorton, Timothy D. McHugh, Mike Brown, Stephen Morris-Jones, Helen Booth, and Judith Breuer
- Subjects
Tuberculosis ,Whole genome sequencing ,Drug resistance ,Clinical samples ,Directly from sputum ,Infectious and parasitic diseases ,RC109-216 - Abstract
Introduction: Resistance to second-line tuberculosis drugs is common, but slow to diagnose with phenotypic drug sensitivity testing. Rapid molecular tests speed up diagnosis, but can only detect limited mutations. Whole genome sequencing (WGS) of culture isolates can generate a complete genetic drug resistance profile, but is delayed by the initial culture step. In the case presented here, successful WGS directly from sputum was achieved using targeted enrichment. Case report: A 29-year-old Nigerian woman was diagnosed with tuberculosis. Xpert MTB/RIF and Hain line probe assays identified rpoB and inhA mutations consistent with rifampicin and intermediate isoniazid resistance, and a further possible mutation conferring fluoroquinolone resistance. WGS directly from sputum identified a further inhA mutation consistent with high-level isoniazid resistance and confirmed the absence of fluoroquinolone resistance. Isoniazid was stopped, and the patient has completed 18 months of a fluoroquinolone-based regimen without relapse. Discussion: Compared to rapid molecular tests (which can only examine a limited number of mutations) and WGS of culture isolates (which requires a culture step), WGS directly from sputum can quickly generate a complete genetic drug resistance profile. In this case, WGS altered the clinical management of drug-resistant tuberculosis and demonstrated potential for guiding individualized drug treatment where second-line drug resistance is common.
- Published
- 2017
- Full Text
- View/download PDF
8. Bedaquiline as Treatment for Disseminated Nontuberculous Mycobacteria Infection in 2 Patients Co-Infected with HIV
- Author
-
Robert F. Miller, Victoria Johnston, Eliza Gil, Veronica Barrett, Michael Brown, Stephen Morris-Jones, and Nicola Sweeney
- Subjects
nontuberculous mycobacteria ,Epidemiology ,lcsh:Medicine ,HIV Infections ,Mycobacterium abscessus ,Antimycobacterial ,chemistry.chemical_compound ,antitubercular drugs ,0302 clinical medicine ,030212 general & internal medicine ,Diarylquinolines ,bedaquiline ,bacteria ,Mycobacteriaceae ,biology ,Coinfection ,Dispatch ,Infectious Diseases ,antiinfective drugs ,NTM ,Microbiology (medical) ,Combination therapy ,medicine.drug_class ,18fluorodeoxyglucose-positron emission tomography/computed tomography imaging ,030231 tropical medicine ,Mycobacterium Infections, Nontuberculous ,Microbiology ,Mycobacterium ,lcsh:Infectious and parasitic diseases ,respiratory infections ,03 medical and health sciences ,co-infection ,Antibiotic resistance ,medicine ,Humans ,viruses ,lcsh:RC109-216 ,antimicrobial resistance ,Adverse effect ,antibacterial drugs ,business.industry ,lcsh:R ,HIV ,biology.organism_classification ,tuberculosis and other mycobacteria ,chemistry ,Bedaquiline as Treatment for Disseminated Nontuberculous Mycobacteria Infection in 2 Patients Co-Infected with HIV ,Nontuberculous mycobacteria ,Bedaquiline ,business ,Mycobacterium avium - Abstract
Nontuberculous mycobacteria can cause disseminated infections in immunocompromised patients and are challenging to treat because of antimicrobial resistance and adverse effects of prolonged multidrug treatment. We report successful treatment with bedaquiline, a novel antimycobacterial drug, as part of combination therapy for 2 patients with disseminated nontuberculous mycobacteria co-infected with HIV.
- Published
- 2021
9. Clinical and Economic Impact of Implementing OVIVA Criteria on Patients With Bone and Joint Infections in Outpatient Parenteral Antimicrobial Therapy
- Author
-
Gabriele Pollara, Tommy Rampling, Imogen Jones, Lucy C K Bell, Sarah Logan, Michael Marks, Stephen Morris-Jones, and Katharina Kranzer
- Subjects
Microbiology (medical) ,medicine.medical_specialty ,Arthritis, Infectious ,medicine.drug_class ,business.industry ,Antibiotics ,OPAT ,OVIVA ,Antimicrobial ,Joint infections ,Anti-Bacterial Agents ,Infectious Diseases ,AcademicSubjects/MED00290 ,Anti-Infective Agents ,Internal medicine ,Outpatients ,medicine ,Ambulatory Care ,Humans ,Brief Reports ,Infusions, Parenteral ,business ,IV antibiotics - Abstract
The OVIVA study demonstrated noninferiority for managing bone and joint infections (BJIs) with oral antibiotics. We report that 79.7% of OPAT patients being treated for BJIs at our center would be eligible for oral antibiotics, saving a median (IQR) 19.5 IV-antibiotic days (8.5–37) and GBP 1234 (569–2594) per patient.
- Published
- 2019
10. Unusual case of Lemierre’s syndrome
- Author
-
Sarah Logan, Stephen Morris-Jones, Arjun Chandna, and Issrah Jawad
- Subjects
0301 basic medicine ,Adult ,Male ,medicine.medical_specialty ,Computed Tomography Angiography ,030106 microbiology ,Penicillins ,Acute Pharyngitis ,Thrombophlebitis ,Sepsis ,Diagnosis, Differential ,03 medical and health sciences ,0302 clinical medicine ,Lemierre's syndrome ,medicine ,Humans ,Internal jugular vein ,Venous Thrombosis ,Unusual Presentation of More Common Disease/Injury ,biology ,business.industry ,Campylobacter rectus ,Anticoagulants ,Pharyngitis ,030206 dentistry ,General Medicine ,Lemierre Syndrome ,Pneumonia ,medicine.disease ,biology.organism_classification ,Surgery ,Anti-Bacterial Agents ,Treatment Outcome ,Fusobacterium ,Acute Disease ,Jugular Veins ,business ,Tomography, X-Ray Computed - Abstract
A young previously healthy patient presented with sepsis and cavitating pneumonia. Campylobacter rectus was isolated from blood cultures and subsequent CT neck showed an internal jugular vein thrombosis. Treatment was with antibiotics, anticoagulation and supportive management. Lemierre’s syndrome is an infectious thrombophlebitis of the internal jugular vein. Although a rare diagnosis since the use of penicillin for treatment of acute pharyngitis, it is being reported with increasing frequency. Usually associated with Fusobacterium spp, we believe that this is the first reported case of Lemierre’s caused by C. rectus—an anaerobic member of the human oral cavity flora, usually associated with localised periodontal disease. The bacillus was isolated from blood during the acute presentation.
- Published
- 2021
11. Leg ulceration due to cutaneous melioidosis in a returning traveller
- Author
-
Stephen Morris-Jones, Christiana Stavrou, Ophelia Veraitch, and Stephen L. Walker
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,Burkholderia pseudomallei ,Melioidosis ,Burkholderia ,medicine.drug_class ,Antibiotics ,tropical medicine (infectious disease) ,Ceftazidime ,Case Report ,030105 genetics & heredity ,03 medical and health sciences ,Wound care ,0302 clinical medicine ,medicine ,Humans ,infections ,Asia, Southeastern ,Ulcer ,Leg ,medicine.diagnostic_test ,Burkholderia thailandensis ,biology ,business.industry ,Australia ,General Medicine ,Thailand ,biology.organism_classification ,medicine.disease ,Dermatology ,dermatology ,Clinical microbiology ,Northern australia ,Skin biopsy ,business ,030217 neurology & neurosurgery ,wound care ,medicine.drug - Abstract
A 26-year-old man, returned to the UK having travelled extensively in Asia. He was referred with a 3-month history of distal leg ulceration following an insect bite while in Thailand. Despite multiple courses of oral antibiotics, he developed two adjacent ulcers. A wound swab isolated an organism identified as Burkholderia thailandensis. The histology of the skin biopsy was non-specific. A diagnosis of cutaneous melioidosis was made, based on clinical and microbiological grounds. The ulcers re-epithelialised on completion of intravenous ceftazidime followed by 3 months of high dose co-trimoxazole and wound care. Many clinical microbiology laboratories have limited diagnostics for security-related organisms, with the result that B. pseudomallei, the causative bacterium of melioidosis, may be misidentified. This case highlights the importance of maintaining high levels of clinical suspicion and close microbiological liaison in individuals returning from South-East Asia and northern Australia with such symptoms.
- Published
- 2021
12. Comprehensive plasma proteomic profiling reveals biomarkers for active tuberculosis
- Author
-
Spiros D. Garbis, Naomi F. Walker, Paul T. Elkington, Cesar Ugarte-Gil, Liku B. Tezera, Diana J. Garay-Baquero, Hannah F. Schiff, Magdalena K. Bielecka, John H. Adamson, Marc Tebruegge, Andres F. Vallejo, Cory H. White, Ben G. Marshall, Robert J. Wilkinson, Christopher H. Woelk, Stephen Morris-Jones, Antigoni Manousopoulou, Wellcome Trust, Royal College of Physicians, and European and Developing Countries Clinical Trial Partnership
- Subjects
0301 basic medicine ,Proteomics ,Male ,Tuberculosis ,Proteome ,Quantitative proteomics ,Computational biology ,03 medical and health sciences ,South Africa ,0302 clinical medicine ,Active tb ,Peru ,medicine ,wf_250 ,Humans ,Gene Regulatory Networks ,Prospective Studies ,Diagnostics ,Tuberculosis, Pulmonary ,Infectious disease ,business.industry ,Proteomic Profiling ,General Medicine ,Mycobacterium tuberculosis ,medicine.disease ,Active tuberculosis ,purl.org/pe-repo/ocde/ford#3.02.00 [https] ,3. Good health ,030104 developmental biology ,ROC Curve ,Infectious disease (medical specialty) ,030220 oncology & carcinogenesis ,Case-Control Studies ,Medicine ,wf_220 ,Female ,wf_200 ,Plasma proteomic ,Clinical Medicine ,business ,Biomarkers ,Follow-Up Studies - Abstract
BACKGROUND Tuberculosis (TB) kills more people than any other infection, and new diagnostic tests to identify active cases are required. We aimed to discover and verify novel markers for TB in nondepleted plasma. METHODS We applied an optimized quantitative proteomics discovery methodology based on multidimensional and orthogonal liquid chromatographic separation combined with high-resolution mass spectrometry to study nondepleted plasma of 11 patients with active TB compared with 10 healthy controls. Prioritized candidates were verified in independent UK (n = 118) and South African cohorts (n = 203). RESULTS We generated the most comprehensive TB plasma proteome to date, profiling 5022 proteins spanning 11 orders-of-magnitude concentration range with diverse biochemical and molecular properties. We analyzed the predominantly low–molecular weight subproteome, identifying 46 proteins with significantly increased and 90 with decreased abundance (peptide FDR ≤ 1%, q ≤ 0.05). Verification was performed for novel candidate biomarkers (CFHR5, ILF2) in 2 independent cohorts. Receiver operating characteristics analyses using a 5-protein panel (CFHR5, LRG1, CRP, LBP, and SAA1) exhibited discriminatory power in distinguishing TB from other respiratory diseases (AUC = 0.81). CONCLUSION We report the most comprehensive TB plasma proteome to date, identifying novel markers with verification in 2 independent cohorts, leading to a 5-protein biosignature with potential to improve TB diagnosis. With further development, these biomarkers have potential as a diagnostic triage test. FUNDING Colciencias, Medical Research Council, Innovate UK, NIHR, Academy of Medical Sciences, Program for Advanced Research Capacities for AIDS, Wellcome Centre for Infectious Diseases Research., Analysis of a comprehensive tuberculosis plasma proteome identified a 5-protein biosignature with potential to improve active tuberculosis diagnosis.
- Published
- 2020
13. Gram-negative bacteraemia; a multi-centre prospective evaluation of empiric antibiotic therapy and outcome in English acute hospitals
- Author
-
Matthew Scarborough, J. Peters, S. Morris-Jones, Tom Rawlinson, Frederick Pink, E.F. Nsutebu, A S Walker, Martin J. Llewelyn, Abid Hussain, Ryan Judge, Joanna Peters, R. Judge, Jennifer Fitzpatrick, J.M. Fitzpatrick, James Price, D.G. Pillay, Mark Melzer, Neil Jenkins, Stephen Morris-Jones, J. Islam, A.J. Lavery, Anita Lavery, Jason Biswas, Gill Jones, Robert Tilley, M.J. Llewelyn, Ed Moran, J.D. Edgeworth, Antonio Querol-Rubiera, N. Jenkins, M. Scarborough, J.R. Price, Jonathan D. Edgeworth, Lucy Guile, Devedas Pillay, Guy E. Thwaites, M. Melzer, Emmanuel Nsutebu, J.S. Biswas, R. Tilley, and F. Pink
- Subjects
0301 basic medicine ,Male ,Microbiology (medical) ,medicine.medical_specialty ,medicine.drug_class ,030106 microbiology ,Antibiotics ,Bacteremia ,Comorbidity ,03 medical and health sciences ,0302 clinical medicine ,Antibiotic resistance ,Risk Factors ,Internal medicine ,Cause of Death ,Severity of illness ,Medicine ,Humans ,Blood culture ,030212 general & internal medicine ,Prospective Studies ,Intensive care medicine ,Prospective cohort study ,Cause of death ,Aged ,Aged, 80 and over ,medicine.diagnostic_test ,business.industry ,General Medicine ,Middle Aged ,medicine.disease ,Anti-Bacterial Agents ,Treatment Outcome ,Infectious Diseases ,England ,Female ,business ,Gram-Negative Bacterial Infections - Abstract
Increasing antibiotic resistance makes choosing antibiotics for suspected Gram-negative infection challenging. This study set out to identify key determinants of mortality among patients with Gram-negative bacteraemia, focusing particularly on the importance of appropriate empiric antibiotic treatment. We conducted a prospective observational study of 679 unselected adults with Gram-negative bacteraemia at ten acute english hospitals between October 2013 and March 2014. Appropriate empiric antibiotic treatment was defined as intravenous treatment on the day of blood culture collection with an antibiotic to which the cultured organism was sensitive in vitro. Mortality analyses were adjusted for patient demographics, co-morbidities and illness severity. The majority of bacteraemias were community-onset (70%); most were caused by Escherichia coli (65%), Klebsiella spp. (15%) or Pseudomonas spp. (7%). Main foci of infection were urinary tract (51%), abdomen/biliary tract (20%) and lower respiratory tract (14%). The main antibiotics used were co-amoxiclav (32%) and piperacillin-tazobactam (30%) with 34% receiving combination therapy (predominantly aminoglycosides). Empiric treatment was inappropriate in 34%. All-cause mortality was 8% at 7 days and 15% at 30 days. Independent predictors of mortality (p0.05) included older age, greater burden of co-morbid disease, severity of illness at presentation and inflammatory response. Inappropriate empiric antibiotic therapy was not associated with mortality at either time-point (adjusted OR 0.82; 95% CI 0.35-1.94 and adjusted OR 0.92; 95% CI 0.50-1.66, respectively). Although our study does not exclude an impact of empiric antibiotic choice on survival in Gram-negative bacteraemia, outcome is determined primarily by patient and disease factors.
- Published
- 2015
14. Iron, but not folic acid, combined with effective antimalarial therapy promotes haematological recovery in African children after acute falciparum malaria
- Author
-
Brian Greenwood, Sarah Meisner, Michael Boele van Hensbroek, Shabbar Jaffar, Stephen Morris-Jones, Lang Bayo, Raduwan Dackour, Christine Phillips, and Other departments
- Subjects
Erythrocyte Indices ,Male ,medicine.medical_specialty ,Anemia ,Sulfadoxine ,Iron ,medicine.medical_treatment ,Parasitemia ,Placebo ,Gastroenterology ,Antimalarials ,Folic Acid ,Chloroquine ,Internal medicine ,Humans ,Medicine ,Prospective Studies ,Malaria, Falciparum ,Child ,biology ,business.industry ,Public Health, Environmental and Occupational Health ,Infant ,Plasmodium falciparum ,General Medicine ,medicine.disease ,biology.organism_classification ,Sulfadoxine/pyrimethamine ,Drug Combinations ,Pyrimethamine ,Infectious Diseases ,Child, Preschool ,Acute Disease ,Immunology ,Drug Therapy, Combination ,Female ,Parasitology ,business ,Malaria ,Follow-Up Studies ,medicine.drug - Abstract
Whether children with malarial anaemia should receive supplementation with iron or folic acid is uncertain. Therefore, the effects of supplementary treatment with iron or folic acid, given together with chloroquine or pyrimethamine-sulfadoxine (Fansidar ® ), has been assessed in 600 Gambian children with uncomplicated falciparum malaria. After one month, haematological recovery was significantly better in the group treated with Fansidar ® than in the chloroquine-treated group (difference in mean haemoglobin level = 0.54 g/dL, P = 0.01). Children who received iron had a significantly better response than those given placebo (differences in mean haemoglobin level after one month and at dry season follow-up = 0.70 g/dL, P = 0.006, and 0.81 g/dL, P = 0.001, respectively). Iron supplementation was not associated with increased prevalence of malaria. Supplementation with folic acid did not improve the haematological response but, among children who received Fansidar ® , the treatment failure rate was significantly higher among those given folic acid than among those given placebo. Thus, supplementation with iron, but not folic acid, improves haematological recovery without increasing susceptibility to malaria.
- Published
- 1995
- Full Text
- View/download PDF
15. Imported Enteric Fever: Case Series from the Hospital for Tropical Diseases, London, United Kingdom
- Author
-
Stephen G. Wright, Margaret Armstrong, Trupti Patel, Stephen Morris-Jones, and Tom Doherty
- Subjects
Adult ,Male ,medicine.medical_specialty ,Veterinary medicine ,Asia ,Nalidixic acid ,Population ,Nigeria ,Salmonella typhi ,Typhoid fever ,Virology ,London ,medicine ,Travel medicine ,Humans ,Typhoid Fever ,education ,education.field_of_study ,Travel ,business.industry ,Tropical disease ,Articles ,Middle Aged ,medicine.disease ,Ciprofloxacin ,Infectious Diseases ,Rose spots ,Parasitology ,Female ,medicine.symptom ,business ,medicine.drug - Abstract
Our current knowledge of the clinical characteristics of enteric fever is drawn mainly from population-based studies in disease-endemic countries, and there are limited data published on cases in returning travelers. We report the clinical characteristics of enteric fever in 92 travelers returning to London, United Kingdom. Salmonella typhi and S. paratyphi resulted in an almost indistinguishable clinical picture. Rose spots and relative bradycardia were found only in a few patients. A total of 91% of the patients had a normal leukocyte count, which was associated with a markedly increased level of alanine aminotransferase in 82%. A total of 57% of the S. typhi isolates had decreased susceptibility to ciprofloxacin and resistance to nalidixic acid; these isolates were from southern Asia. Thirty percent were multidrug resistant; all were from southern Asia and Nigeria. None of the paratyphoid isolates were multidrug resistant but rates of decreased susceptibility to fluoroquinolones were higher than in S. typhi (74%).
- Published
- 2010
16. Synthesis of Melanin Pigment by Candida albicans In Vitro and during Infection
- Author
-
Martha Eugenia Urán, Stephen Morris-Jones, Joshua D. Nosanchuk, Andrew J. Hamilton, Rachael Morris-Jones, Arturo Casadevall, Beatriz L. Gómez, and Soraya Díez
- Subjects
Male ,Immunology ,Virulence ,Enzyme-Linked Immunosorbent Assay ,Immunofluorescence ,Microbiology ,Pathogenesis ,Melanin ,Mice ,Candida albicans ,medicine ,Animals ,Melanins ,Mice, Inbred BALB C ,medicine.diagnostic_test ,biology ,integumentary system ,Candidiasis ,Fungi imperfecti ,biology.organism_classification ,Corpus albicans ,In vitro ,Infectious Diseases ,Microscopy, Electron, Scanning ,Parasitology ,sense organs ,Fungal and Parasitic Infections - Abstract
Melanins are implicated in the pathogenesis of several important human diseases. This study confirmed the presence of melanin particles in Candida albicans in vitro and during infection. Dark particles were isolated from the digestion of C. albicans cultures and from infected tissue, as established by electron microscopy and immunofluorescence techniques.
- Published
- 2005
17. Shigella sonnei Outbreak among Homosexual Men, London
- Author
-
Oliver Morgan, Paul Crook, Tom Cheasty, Brian Jiggle, Isabelle Giraudon, Harriett Hughes, Stephen-Morris Jones, and Helen Maguire
- Subjects
Shigella sonnei ,HIV ,homosexuality ,disease outbreaks ,letter ,United Kingdom ,Medicine ,Infectious and parasitic diseases ,RC109-216 - Published
- 2006
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.